{
    "clinical_study": {
        "@rank": "80781", 
        "arm_group": {
            "arm_group_label": "Flector Patch", 
            "arm_group_type": "Experimental", 
            "description": "Flector Patch is a transdermal delivery system containing 180 mg of diclofenac hydroxyethylpyrrolidine.  The patch will be used twice-a-day for up to two weeks, or until pain resolution, whichever comes first."
        }, 
        "brief_summary": {
            "textblock": "The primary purpose of this study is to determine whether Flector Patch is safe for use in\n      children.  The secondary purpose is to assess blood levels of diclofenac, the active\n      ingredient in Flector Patch."
        }, 
        "brief_title": "Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Athletic Injuries", 
        "condition_browse": {
            "mesh_term": [
                "Athletic Injuries", 
                "Soft Tissue Injuries", 
                "Wounds and Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 6 to 16 years, either gender\n\n          -  Must sign informed consent along with their parent\n\n          -  Minor soft tissue injury (mild or moderate sprain, strain, or contusion) within 48\n             hours of study entry\n\n          -  Spontaneous pain of at least moderate intensity (i.e. pain of at least 3 on the\n             6-point Wong- Baker Faces scale for pain severity assessment by patient)\n\n          -  Injury must be considered by the Investigator to be clinically significant\n\n          -  Negative urine pregnancy test at screening for female subjects of childbearing\n             potential (12-16 years)\n\n          -  Able to read and speak English\n\n          -  Available with their parents for the immediate two week period following study\n             enrollment\n\n        Exclusion Criteria:\n\n          -  Major soft tissue injury (fracture, severe second degree or greater tear of\n             ligament/muscle/ tendon, or common nerve injury)\n\n          -  Open skin lesion or any dermatological condition (e.g. skin infection, eczema) within\n             the injured area\n\n          -  Injury is midline or involves the spine, digits or hands\n\n          -  Prior injury to the same site within the past 3 months\n\n          -  Three or more other prior injuries (minor or major) to the region in the past\n\n          -  Injury occurred more than 48 hours prior to study entry\n\n          -  Prior use of topical medication to involved area within 48 hours of study entry\n\n          -  Allergic disorders, including asthma or urticaria, but only if associated with\n             exposure to aspirin or an NSAID\n\n          -  Coagulation defects\n\n          -  Prior use of over-the-counter (OTC) analgesics or short-acting non-steroidal\n             anti-inflammatory drugs (NSAIDs [ibuprofen, ketoprofen]) within 6 hours of study\n             entry (acetaminophen permitted up until the time of study entry)\n\n          -  Prior use of narcotic analgesics within 7 days of study entry\n\n          -  Prior use of systemic anti-inflammatory steroidal drugs within 60 days of study entry\n\n          -  Prior use of long-acting NSAIDs such as piroxicam or naproxen since injury\n\n          -  Concomitant use of drugs which may be susceptible to interactions with diclofenac, or\n             affect safety if used concomitantly (lithium, digoxin, anticoagulants, antidiabetic\n             agents, cyclosporin, methotrexate, quinolone antimicrobials, other NSAIDs, steroids\n             and diuretics)\n\n          -  Subjects suffering from psychiatric disorders\n\n          -  Handicapped patients, but only if the handicap prevents them from either assessing\n             their pain or safely using the patch (e.g., pervasive developmental disorders such as\n             autism, Asperger syndrome, Rett syndrome, Heller's syndrome, severe attention deficit\n             hyperactivity disorders (ADHD), other severe mental retardation of traumatic,\n             congenital or other origin)\n\n          -  History of current alcohol or drug abuse dated < 1 year\n\n          -  Severe cardiac, renal or hepatic impairment\n\n          -  Severe systemic diseases (e.g. cancer, severe acute infection)\n\n          -  Any underlying disease or medication that severely compromise the patient's immune\n             system\n\n          -  Prior history of any chronic pain disorder\n\n          -  Prior history of GI bleeds/ulcers, liver or kidney disease\n\n          -  Hypersensitivity to diclofenac or other NSAID drugs (including aspirin)\n\n          -  Females who are pregnant or breast feeding\n\n          -  Patients participating or having been involved in other clinical investigations\n             during the three months preceding the entry of this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "16 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02132247", 
            "org_study_id": "08US/Fp03"
        }, 
        "intervention": {
            "arm_group_label": "Flector Patch", 
            "intervention_name": "Diclofenac hydroxyethylpyrrolidine", 
            "intervention_type": "Drug", 
            "other_name": "Flector Patch"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Diclofenac", 
                "Diclofenac hydroxyethylpyrrolidine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Minor athletic injuries", 
            "Pain", 
            "Diclofenac", 
            "Topical"
        ], 
        "lastchanged_date": "May 20, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Orem", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84057"
                    }, 
                    "name": "Utah Valley Pediatrics"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "West Point", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84015"
                    }, 
                    "name": "Legacy Point Family Medicine"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Prospective, Uncontrolled Study of the Safety and Local Tolerability of the Diclofenac Epolamine Patch (Flector Patch) in Pediatric Patients With Minor Soft Tissue Injuries", 
        "overall_contact": {
            "email": "chris@ibsa-us.com", 
            "last_name": "Christopher Jones, Ph.D.", 
            "phone": "(801) 582-0639"
        }, 
        "overall_official": {
            "affiliation": "IBSA Institut Biochimique SA", 
            "last_name": "Clarence Jones, Ph.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "None - 0; Faint redness - 1; Moderate redness - 2; Intense redness - 3; Redness with edema or papules - 4; Redness with weeping vesicles, blisters or bullae - 5; Redness with extension of effect beyond margin of contact site - 6.", 
            "measure": "Dermatologic assessment at the patch application site", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 2 weeks, depending upon pain resolution"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02132247"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "5-point scale: No clinical improvement in pain intensity and/or functional performance - 1; Slight clinical improvement in pain intensity and/or functional performance - 2; Moderate clinical improvement in pain intensity and/or functional performance - 3; Marked clinical improvement in pain intensity and/or functional performance - 4; Restoration of normal functional performance in the absence of any pain - 5.", 
                "measure": "Investigator assessment of the global response to therapy on a 5-point scale", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 weeks, depending upon pain resolution"
            }, 
            {
                "description": "Wong-Baker Faces Scale 6-point scale:\nNo Hurt - 0; Hurts Little Bit - 1; Hurts Little More - 2; Hurts Even More - 3; Hurts Whole Lot - 4; Hurts Worst - 5.", 
                "measure": "Patient assessment of pain on a 6-point scale", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 weeks, depending upon pain resolution"
            }, 
            {
                "measure": "Plasma concentration of diclofenac", 
                "safety_issue": "Yes", 
                "time_frame": "Day 2 and either Day 4, 7 or 14, depending upon pain resolution"
            }
        ], 
        "source": "IBSA Institut Biochimique SA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "IBSA Institut Biochimique SA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}